mTOR and cancer: insights into a complex relationship

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216

Upstream and downstream of mTOR

Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181

TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival

Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083

mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery

Kim, D., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument‐Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 3,051

Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton

Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665

mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt

O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561

Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB

Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Rüegg, M. A., Hall, A., & Hall, M. N. (2004) · Nature Cell Biology · doi:10.1038/ncb1183 · Cited by 2,097

Two TOR Complexes, Only One of which Is Rapamycin Sensitive, Have Distinct Roles in Cell Growth Control

Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P., & Hall, M. N. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00636-6 · Cited by 1,886

A Systems Biology Roadmap to Decode mTOR Control System in Cancer

Dorvash, M., Farahmandnia, M., & Tavassoly, I. (2019) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-019-00347-6 · Cited by 36

How can we turn the PI3K/AKT/mTOR pathway down? Insights into inhibition and treatment of cancer

Afify, S. M., Oo, A. K. K., Hassan, G., Seno, A., & Seno, M. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1918001 · Cited by 36

Decreased lactate concentration and glycolytic enzyme expression reflect inhibition of mTOR signal transduction pathway in B‐cell lymphoma

Lee, S., Marzec, M., Liu, X., Wehrli, S. L., Kantekure, K., Puthiyaveettil, R., NELSON, D. S., Delikatny, E. J., Glickson, J. D., & Wasik, M. A. (2012) · NMR in Biomedicine · doi:10.1002/nbm.2825 · Cited by 36

Evi1 forms a bridge between the epigenetic machinery and signaling pathways

Yoshimi, A., & Kurokawa, M. (2011) · Oncotarget · doi:10.18632/oncotarget.304 · Cited by 36

PIH1D1 interacts with mTOR complex 1 and enhances ribosome RNA transcription

Kamano, Y., Saeki, M., Egusa, H., Kakihara, Y., Houry, W. A., Yatani, H., & Kamisaki, Y. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.09.001 · Cited by 44

An Emerging Role for IQGAP1 in Regulating Protein Traffic

Osman, M. A. (2010) · The Scientific World JOURNAL · doi:10.1100/tsw.2010.85 · Cited by 34

PIM‐2 is an independent regulator of chondrocyte survival and autophagy in the epiphyseal growth plate

Bohensky, J., Shapiro, I. M., Leshinsky, S., Watanabe, H., & Srinivas, V. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21117 · Cited by 36

Dual Functional LipoMET Mediates Envelope-type Nanoparticles to Combinational Oncogene Silencing and Tumor Growth Inhibition

Shi, K., Zhao, Y. D., Miao, L., Satterlee, A., Haynes, M. T., Luo, C., Musetti, S., & Huang, L. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.02.008 · Cited by 36

eIF4E3 forms an active eIF4F complex during stresses (eIF4FS) targeting mTOR and re-programs the translatome

Weiss, B., Allen, G. E., Kloehn, J., Abid, K., Jaquier-Gubler, P., & Curran, J. A. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab267 · Cited by 34

The translational oscillation in oocyte and early embryo development

Iyyappan, R., Aleshkina, D., Ming, H., Dvoran, M., Kakavand, K., Jansová, D., Llano, E. D., Gahurová, L., Bruce, A. W., Mašek, T., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad996 · Cited by 32

DNA-PKcs is important for Akt activation and gemcitabine resistance in PANC-1 pancreatic cancer cells

Hu, H., Gu, Y., Yi, Q., Hu, B., Zhu, C., Wang, G., & Li, J.-P. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.08.059 · Cited by 35

The PI-3kinase pathway in hematopoietic stem cells and leukemia-initiating cells: A mechanistic difference between normal and cancer stem cells

Yilmaz, Ö. H., & Morrison, S. J. (2008) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2008.02.004 · Cited by 37

Selective concomitant inhibition of mTORC1 and mTORC2 activity in estrogen receptor negative breast cancer cells by BN107 and oleanolic acid

Chu, R. A., Zhao, X., Griffin, C. A., Staub, R. E., Shoemaker, M., Climent, J., Leitman, D. C., Cohen, I. V., Shtivelman, E., & Fong, S. (2009) · International Journal of Cancer · doi:10.1002/ijc.25116 · Cited by 36

Tetraspanin 8-Rictor-Integrin α3 Complex Is Required for Glioma Cell Migration

Pan, S., Zhan, S., Pan, Y., Liu, W., Bian, L., Sun, B., & Sun, Q. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16035363 · Cited by 35

Targeting of tumor endothelial cells combining 2 Gy/day of X‐ray with Everolimus is the effective modality for overcoming clinically relevant radioresistant tumors

Kuwahara, Y., Mori, M., Kitahara, S., Fukumoto, M., Ezaki, T., Mori, S., Echigo, S., Ohkubo, Y., & Fukumoto, M. (2014) · Cancer Medicine · doi:10.1002/cam4.185 · Cited by 35

Rapamycin for longevity: the pros, the cons, and future perspectives

Roark, K. M., & Iffland, P. H. (2025) · Frontiers in Aging · doi:10.3389/fragi.2025.1628187 · Cited by 37

The physiology and pathophysiology of rapamycin resistance

Gruppuso, P. A., Boylan, J. M., & Sanders, J. A. (2011) · Cell Cycle · doi:10.4161/cc.10.7.15230 · Cited by 34

An overview of the mTOR pathway as a target in cancer therapy

Gentzler, R. D., Altman, J. K., & Platanias, L. C. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.677439 · Cited by 36

Signal transduction inhibitors and antiangiogenic therapies for malignant glioma

Mellinghoff, I. K., Lassman, A. B., & Wen, P. Y. (2011) · Glia · doi:10.1002/glia.21137 · Cited by 34

Metformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived Xenografts

Lipner, M. B., Marayati, R., Deng, Y., Wang, X., Raftery, L., O’Neil, B. H., & Yeh, J. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147113 · Cited by 35

Pharmacological Inhibition of mTORC2 Reduces Migration and Metastasis in Melanoma

Guenzle, J., Akasaka, H., Joechle, K., Reichardt, W., Venkatasamy, A., Hoeppner, J., Hellerbrand, C., Fichtner‐Feigl, S., & Lang, S. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010030 · Cited by 34

Targeting the mTOR pathway using novel ATP‑competitive inhibitors, Torin1, Torin2 and XL388, in the treatment of glioblastoma

Amin, A. G., Eong, S., Gillick, J. L., Sursal, T., Murali, R., Gandhi, C. D., & Jhanwar‐Uniyal, M. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5263 · Cited by 36

The impact of DAPK1 and mTORC1 signaling association on autophagy in cancer

Movahhed, P., Saberiyan, M., Safi, A., Arshadi, Z., Kazerouni, F., & Teimori, H. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07154-1 · Cited by 34

Enhanced interaction between Hsp90 and raptor regulates mTOR signaling upon T cell activation

Delgoffe, G. M., Kole, T. P., Cotter, R. J., & Powell, J. D. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.05.185 · Cited by 34

The abundance and activation of mTORC1 regulators in skeletal muscle of neonatal pigs are modulated by insulin, amino acids, and age

Suryawan, A., & Davis, T. A. (2010) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00428.2010 · Cited by 34

Novel inhibitors in development for hepatocellular carcinoma

Wörns, M., & Galle, P. R. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543781003767418 · Cited by 34

Proteomics: a strategy to understand the novel targets in protein misfolding and cancer therapy

Nagathihalli, N. S., Singh, O. V., & Merchant, N. B. (2010) · Expert Review of Proteomics · doi:10.1586/epr.10.70 · Cited by 34

Tumor growth in patients with tuberous sclerosis complex on the ketogenic diet

Chu, C. J., & Thiele, E. A. (2009) · Brain and Development · doi:10.1016/j.braindev.2009.04.009 · Cited by 34

Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy- d -glucose under hypoxia in lung cancer cell lines

Wangpaichitr, M., Savaraj, N., Maher, J. C., Kurtoğlu, M., & Lampidis, T. J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2334 · Cited by 35

Targeting the mTOR/4E-BP Pathway in Endometrial Cancer

Korets, S. B., Czok, S., Blank, S. V., Curtin, J. P., & Schneider, R. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1664 · Cited by 34

Farrerol inhibited angiogenesis through Akt/mTOR, Erk and Jak2/Stat3 signal pathway

Dai, F., Gao, L., Zhao, Y., Wang, C., & Xie, S. (2016) · Phytomedicine · doi:10.1016/j.phymed.2016.03.008 · Cited by 34

Autophagy in protists and their hosts: When, how and why?

Romano, P. S., Akematsu, T., Besteiro, S., Bindschedler, A., Carruthers, V. B., Chahine, Z. M., Coppens, I., Descoteaux, A., Duque, T. L. A., He, C. Y., et al. (2023) · Autophagy Reports · doi:10.1080/27694127.2022.2149211 · Cited by 33

Morphoproteomic analysis reveals an overexpressed and constitutively activated phospholipase D1-mTORC2 pathway in endometrial carcinoma.

Shen, Q., Stanton, M., Feng, W., Rodriguez, M. E., Ramondetta, L. M., Chen, L., Brown, R. E., & Duan, X. (2010) · PubMed Central · Cited by 33

EGFR-AKT-mTOR activation mediates epiregulin-induced pleiotropic functions in cultured osteoblasts

Fan, J., Liu, W., Zhu, X., Yuan, K., Xu, D., Chen, J., & Cui, Z. (2014) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-014-2210-4 · Cited by 33

Past, Present and Future of Targeted Therapy in Solid Tumors

Palazzo, A., Iacovelli, R., & Cortesi, E. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910791517145 · Cited by 33

Effect of sirolimus on urinary bladder cancer T24 cell line

Pinto‐Leite, R., Botelho, P. S. P. S., Ribeiro, E., Oliveira, P. A., & Santos, L. L. (2009) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-28-3 · Cited by 35

Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?

Montella, L., Palmieri, G., Addeo, R., & Prete, S. D. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i27.6114 · Cited by 33

Efficacy of Palbociclib Combinations in Hormone Receptor–Positive Metastatic Breast Cancer Patients After Prior Everolimus Treatment

Dhakal, A., Matthews, C. M., Levine, E. G., Salerno, K. E., Zhang, F., Takabe, K., Early, A., Edge, S. B., O'Connor, T., Khoury, T., et al. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.04.015 · Cited by 34

The Anti-Non-Small Cell Lung Cancer Cell Activity by a mTOR Kinase Inhibitor PQR620

Zha, J., Xia, Y., Ye, C.-L., Hu, Z., Zhang, Q., Han, X., Yu, B., Xu, W., & Xu, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.669518 · Cited by 33

Targeted therapy for sarcomas

Forscher, C. A., Figlin, R. A., & Mita, M. M. (2014) · Biologics · doi:10.2147/btt.s26555 · Cited by 32

Insight into the role of mTOR and metabolism in T cells reveals new potential approaches to preventing graft rejection

Lo, Y.-C., Lee, C.-F., & Powell, J. D. (2014) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000098 · Cited by 33

Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells

You, K. S., Yi, Y. W., Kwak, S., & Seong, Y. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4244 · Cited by 31

mTOR-dependent upregulation of xCT blocks melanin synthesis and promotes tumorigenesis

Li, C., Chen, H., Zhou, L., He, S., Chen, R., Wang, F., Liu, Z., Li, K., Cheng, L., Liu, Y., et al. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0274-0 · Cited by 33

Endolysosomal TRPMLs in Cancer

Xu, M., & Dong, X. (2021) · Biomolecules · doi:10.3390/biom11010065 · Cited by 33

Everolimus – a new approach in the treatment of renal cell carcinoma

Eisen, T. G. (2010) · Cancer Management and Research · doi:10.2147/cmar.s6047 · Cited by 32

Signaling through EAAT-1/GLAST in cultured Bergmann glia cells

Martínez‐Lozada, Z., Hernández‐Kelly, L. C., Aguilera, J., López‐Bayghen, E., & Ortega, A. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.07.015 · Cited by 33

Thioredoxin‐interacting protein deficiency alleviates phenotypic alterations of podocytes via inhibition of mTOR activation in diabetic nephropathy

Song, S., Qiu, D., Shi, Y., Wang, S., Zhou, X., Chen, N., Wei, J., Wu, M. T., Wu, H., & Duan, H. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28317 · Cited by 33

Dual targeting of mTORC1 and mTORC2 by INK-128 potently inhibits human prostate cancer cell growth in vitro and in vivo

Jiang, S., & Wang, S. (2015) · Tumor Biology · doi:10.1007/s13277-015-3536-6 · Cited by 32

Recent Advances in Renal Tumors with TSC/mTOR Pathway Abnormalities in Patients with Tuberous Sclerosis Complex and in the Sporadic Setting

Kapur, P., Brugarolas, J., & Trpkov, K. (2023) · Cancers · doi:10.3390/cancers15164043 · Cited by 32

The planarian P2X homolog in the regulation of asexual reproduction

Sakurai, T., Lee, H., Kashima, M., Saito, Y., Hayashi, T., Kudome, T., Nishimura, O., Agata, K., & Shibata, N. (2012) · The International Journal of Developmental Biology · doi:10.1387/ijdb.113439ts · Cited by 31

Predicting mTOR Inhibitors with a Classifier Using Recursive Partitioning and Naïve Bayesian Approaches

Wang, L., Chen, L., Liu, Z., Zheng, M., Gu, Q., & Xu, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095221 · Cited by 31

A Phase I Trial of IGF-1R Inhibitor Cixutumumab and mTOR Inhibitor Temsirolimus in Metastatic Castration-resistant Prostate Cancer

McHugh, D. J., Chudow, J., DeNunzio, M., Slovin, S. F., Danila, D. C., Morris, M. J., Scher, H. I., & Rathkopf, D. E. (2020) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.10.013 · Cited by 31

TXNIP deficiency mitigates podocyte apoptosis via restraining the activation of mTOR or p38 MAPK signaling in diabetic nephropathy

Song, S., Qiu, D., Wang, Y., Wei, J., Wu, H., Wu, M. T., Wang, S., Zhou, X., Shi, Y., & Duan, H. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.111862 · Cited by 33

The IGF-1 network in lung carcinoma therapeutics

Karamouzis, M. V., & Papavassiliou, A. G. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.10.003 · Cited by 31

TNF-α promotes human retinal pigment epithelial (RPE) cell migration by inducing matrix metallopeptidase 9 (MMP-9) expression through activation of Akt/mTORC1 signaling

Wang, C., Cao, G.-F., Jiang, Q. L., & Yao, J. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.07.044 · Cited by 31

Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function

Szalontay, L., Schally, A. V., Popovics, P., Vidaurre, I., Krishan, A., Zarándi, M., Cai, R., Klukovits, A., Block, N. L., & Rick, F. G. (2014) · Cell Cycle · doi:10.4161/15384101.2015.945879 · Cited by 31

The Multiple Mechanisms of Cell Death Triggered by Resveratrol in Lymphoma and Leukemia

Frazzi, R., & Tigano, M. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15034977 · Cited by 32

DEPTOR has growth suppression activity against pancreatic cancer cells

Li, H., Sun, G. Y., Zhao, Y., Thomas, D. G., Greenson, J. K., Zalupski, M. M., Ben‐Josef, E., & Sun, Y. (2014) · Oncotarget · doi:10.18632/oncotarget.2659 · Cited by 30

Statins in Lymphangioleiomyomatosis. Simvastatin and Atorvastatin Induce Differential Effects on tuberous sclerosis complex 2 –Null Cell Growth and Signaling

Atochina‐Vasserman, E. N., Goncharov, D. A., Volgina, A., Milavec, M., James, M. L., & Krymskaya, V. P. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0203rc · Cited by 30

Activated growth signaling pathway expression in Ewing sarcoma and clinical outcome

Mora, J., Rodríguez, E., de Torres, C., Cardesa‐Salzmann, T. M., Ríos, J., Hernández, T., Cardesa, A., & de Álava, E. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23348 · Cited by 30

Mammalian target of rapamycin complex 1 (mTORC1) signaling in energy balance and obesity

Cota, D. (2009) · Physiology & Behavior · doi:10.1016/j.physbeh.2009.03.006 · Cited by 32

Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: a new rationale supporting CD44-induced AML differentiation therapy

Gadhoum, S. Z., Madhoun, N. Y. R., Abuelela, A. F., & Merzaban, J. S. (2016) · Leukemia · doi:10.1038/leu.2016.221 · Cited by 30

Mice endometrium receptivity in early pregnancy is impaired by maternal hyperinsulinemia

Li, R., Wu, J., He, J., Wang, Y., Liu, X., Chen, X., Tong, C., Ding, Y., Su, Y., Chen, W., et al. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6322 · Cited by 30

GDC-0349 inhibits non-small cell lung cancer cell growth

Yang, H., Zhao, J., Zhao, M., Zhao, L., Zhou, L.-N., Duan, Y., & Li, G. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03146-w · Cited by 30

Regulation of DNA duplication by the mTOR signaling pathway

He, Z., Houghton, P. J., Williams, T. M., & Shen, C. (2021) · Cell Cycle · doi:10.1080/15384101.2021.1897271 · Cited by 30

The mitochondrial protein YME1 Like 1 is important for non-small cell lung cancer cell growth

Xia, Y., He, C., Hu, Z., Wu, Z., Hui, Y., Liu, Y.-Y., Mu, C., & Zha, J. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.82217 · Cited by 29

Inhibition of 14-3-3 binding to Rictor of mTORC2 for Akt phosphorylation at Ser473 is regulated by selenoprotein W

Jeon, Y. H., Park, Y. H., Kwon, J. H., Lee, J. H., & Kim, I. Y. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.05.005 · Cited by 30

An Orthotopic Model of Metastatic Nasopharyngeal Carcinoma and Its Application in Elucidating a Therapeutic Target That Inhibits Metastasis

Smith, P. A., Merritt, D., Barr, L., & Thorley‐Lawson, D. A. (2011) · Genes & Cancer · doi:10.1177/1947601912440878 · Cited by 30

Overproduction of Cyclin D1 is dependent on activated mTORC1 signal in nasopharyngeal carcinoma: Implication for therapy

Huang, X., Dai, C.-B., Mou, Z.-L., Wang, L., Wen, W., Shu-guang, L., Xu, G., & Li, H. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.01.020 · Cited by 30

Translational responses to growth factors and stress

Cully, M., & Downward, J. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370284 · Cited by 30

Potent, Selective, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin Kinase Domain Exhibiting Single Agent Antiproliferative Activity

Koehler, M. F. T., Bergeron, P., Blackwood, E. R., Bowman, K. K., Chen, Y., Deshmukh, G. S., Ding, X., Epler, J., Lau, K., Lee, L. B., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301389h · Cited by 29

Loss of heterozygosity by SCRaMbLEing

Li, Y., Wu, Y., Ma, L., Guo, Z., Xiao, W., & Yuan, Y. (2019) · Science China Life Sciences · doi:10.1007/s11427-019-9504-5 · Cited by 29

The class I PI3K/Akt pathway is critical for cancer cell survival in dogs and offers an opportunity for therapeutic intervention

Chen, Y., Tan, K. A. L., Pang, L. Y., & Argyle, D. J. (2012) · BMC Veterinary Research · doi:10.1186/1746-6148-8-73 · Cited by 30

Optimization of Energy-Consuming Pathways towards Rapid Growth in HPV-Transformed Cells

Mizrachy‐Schwartz, S., Kravchenko‐Balasha, N., Ben‐Bassat, H., Klein, S., & Levitzki, A. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000628 · Cited by 29

Interferon γ (IFNγ) Signaling via Mechanistic Target of Rapamycin Complex 2 (mTORC2) and Regulatory Effects in the Generation of Type II Interferon Biological Responses

Kroczynska, B., Rafidi, R. L., Majchrzak-Kita, B., Kosciuczuk, E. M., Blyth, G. T., Jemielity, J., Warminska, Z., Saleiro, D., Mehrotra, S., Arslan, A. D., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.664995 · Cited by 29

Transforming somatic mutations of mammalian target of rapamycin kinase in human cancer

Yamaguchi, H., Kawazu, M., Yasuda, T., Soda, M., Ueno, T., Kojima, S., Yashiro, M., Yoshino, I., Ishikawa, Y., Sai, E., et al. (2015) · Cancer Science · doi:10.1111/cas.12828 · Cited by 28

Discovery of triazine-benzimidazoles as selective inhibitors of mTOR

Peterson, E. A., Andrews, P. S., Be, X., Boezio, A. A., Bush, T. L., Cheng, A. C., Coats, J. R., Colletti, A. E., Copeland, K. W., DuPont, M. M., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.02.007 · Cited by 29

Use of Oral Antidiabetic Drugs (Metformin and Pioglitazone) in Diabetic Patients with Breast Cancer: How Does It Effect on Serum Hif-1 Alpha and 8Ohdg Levels?

Harman, E., Erten, Ç., Küçükzeybek, Y., Dırıcan, A., Er, H., & Oktay, T. M. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.10.5143 · Cited by 29

Expression profiling of 21 biomolecules in locally advanced nasopharyngeal carcinomas of Caucasian patients

Krikelis, D., Bobos, M., Karayannopoulou, G., Resiga, L., Chrysafi, S., Samantas, E., Andreopoulos, D., Vassiliou, V., Ciuleanu, E., & Fountzilas, G. (2013) · BMC Clinical Pathology · doi:10.1186/1472-6890-13-1 · Cited by 29

Cullin 3 and Its Role in Tumorigenesis

Chen, R. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-1025-0_12 · Cited by 29

Cancer cell-specific cGAS/STING Signaling pathway in the era of advancing cancer cell biology

Kumar, V., Bauer, C., & Stewart, J. H. (2023) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2023.151338 · Cited by 33

Glucose-dependent insulinotropic polypeptide stimulates the proliferation of colorectal cancer cells

Prabakaran, D., Wang, B., Feuerstein, J. D., Sinclair, J. A., Bijpuria, P., Jepeal, L. I., & Wolfe, M. M. (2010) · Regulatory Peptides · doi:10.1016/j.regpep.2010.04.005 · Cited by 29

Combined RNAi-Mediated Suppression of Rictor and EGFR Resulted in Complete Tumor Regression in an Orthotopic Glioblastoma Tumor Model

Verreault, M., Weppler, S. A., Stegeman, A., Warburton, C., Strutt, D., Masin, D., & Bally, M. B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059597 · Cited by 29

The Immunosuppressive drug – Rapamycin – Electroanalytical Sensing Using Boron- Doped Diamond electrode

Stanković, D. M., & Kalcher, K. (2015) · Electrochimica Acta · doi:10.1016/j.electacta.2015.03.200 · Cited by 29

The mTOR Signaling Pathway is an Emerging Therapeutic Target in Multiple Myeloma

Li, J., Zhu, J., Cao, B., & Mao, X. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990638 · Cited by 28

Experimental Evolution Reveals Interplay between Sch9 and Polyploid Stability in Yeast

Lu, Y.-J., Swamy, K. B. S., & Leu, J. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006409 · Cited by 26

Recent Advances in Marine-Derived Bioactives Towards Cancer Therapy

Tamzi, N. N., Rahman, M. M., & Das, S. (2024) · International Journal of Translational Medicine · doi:10.3390/ijtm4040051 · Cited by 29

Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non–muscle invasive bladder cancer

Fahmy, M. A., Mansure, J. J., Brimo, F., Yafi, F. A., Segal, R., Althunayan, A. M., Hicks, J. L., Meeker, A. K., Netto, G. J., & Kassouf, W. (2013) · Human Pathology · doi:10.1016/j.humpath.2012.11.026 · Cited by 28

A Multi-Lineage Screen Reveals mTORC1 Inhibition Enhances Human Pluripotent Stem Cell Mesendoderm and Blood Progenitor Production

Nazareth, E. J. P., Rahman, N., Yin, T., & Zandstra, P. W. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.04.003 · Cited by 28

A review on the role of fatty acids in colorectal cancer progression

Hoxha, M., & Zappacosta, B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1032806 · Cited by 29

Regulation of APCCdh1 E3 ligase activity by the Fbw7/cyclin E signaling axis contributes to the tumor suppressor function of Fbw7

Lau, A. W., Inuzuka, H., Fukushima, H., Wan, L., Liu, P., Gao, D., Sun, Y., & Wei, W. (2013) · Cell Research · doi:10.1038/cr.2013.67 · Cited by 28

Targeted Therapies in the Treatment of Advanced Hepatocellular Carcinoma

Wei, Z., Doria, C., & Liu, Y. (2013) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s7633 · Cited by 28

13C MRS and LC–MS Flux Analysis of Tumor Intermediary Metabolism

Shestov, A. A., Lee, S., Nath, K., Guo, L., NELSON, D. S., Roman, J. C., Leeper, D. B., Wasik, M. A., Blair, I. A., & Glickson, J. D. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00135 · Cited by 28

LHX2 promotes malignancy and inhibits autophagy via mTOR in osteosarcoma and is negatively regulated by miR-129-5p

Song, H., Liu, J., Wu, X., Zhou, Y., Chen, X., Chen, J., Deng, K., Mao, C., Huang, S.-H., & Liu, Z. (2019) · Aging · doi:10.18632/aging.102427 · Cited by 28

The novel mTORC1/2 dual inhibitor INK-128 suppresses survival and proliferation of primary and transformed human pancreatic cancer cells

Lou, H., Weng, X.-C., Pan, H., Qin, P., Sun, P., Liu, L.-L., & Chen, B. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.06.081 · Cited by 27

CHO cells knocked out for TSC2 display an improved productivity of antibodies under fed batch conditions

McVey, D., Aronov, M., Rizzi, G., Cowan, A. J., Scott, C., Megill, J. R., Russell, R. J., & Tirosh, B. (2016) · Biotechnology and Bioengineering · doi:10.1002/bit.25951 · Cited by 27

Glutamine metabolism targeting liposomes for synergistic chemosensitization and starvation therapy in ovarian cancer

Cai, X., Shi, S., Chen, G., Zhong, M., Yang, Y., Mai, Z., Tian, Y., Tan, J., He, L., Cui, C., et al. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.12.052 · Cited by 27

The Mammalian target of rapamycin inhibitors in breast cancer: current evidence and future directions.

Malaguti, P., Vari, S., Cognetti, F., & Fabi, A. (2013) · PubMed · Cited by 27

Cancer therapy targeted at cellular signal transduction mechanisms: Strategies, clinical results, and unresolved issues

Christoffersen, T., Guren, T. K., Spindler, K. G., Dahl, O., Lønning, P. E., & Gjertsen, B. T. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.10.009 · Cited by 26

Inhibition of human in-stent restenosis: a molecular view

Giordano, A., & Romano, A. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.03.006 · Cited by 27

Drug discovery targeting the mTOR pathway

Martelli, A. M., Buontempo, F., & McCubrey, J. A. (2018) · Clinical Science · doi:10.1042/cs20171158 · Cited by 77

TOR (target of rapamycin) as an anti-cancer target

Bousquet, G., Dreyer, C., Faivre, S. J., & Raymond, É. (2007) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2008.04.004 · Cited by 2

Mammalian Target of Rapamycin (mTOR) Signalling Pathway-A Potential Target for Cancer Intervention: A Short Overview

Basnet, R., Basnet, B. B., Gupta, R., Basnet, T. B., Khadka, S., & Alam, M. S. (2023) · Current Molecular Pharmacology · doi:10.2174/1874467217666230331081959 · Cited by 11

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

Wander, S. A., Hennessy, B. T., & Slingerland, J. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44145 · Cited by 427

Unveiling the Role of Mechanistic Target of Rapamycin Kinase (MTOR) Signaling in Cancer Progression and the Emergence of MTOR Inhibitors as Therapeutic Strategies

Mehta, D., Rajput, K., Jain, D., Bajaj, A., & Dasgupta, U. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00530 · Cited by 25